Description
The Myasthenia Gravis (MG) Blood Test Panel is a group of tests that help diagnose and monitor myasthenia gravis, an autoimmune disorder that affects nerve-to-muscle communication, leading to muscle weakness and fatigue.
Purpose of the Panel
- Diagnose myasthenia gravis: Detects antibodies that interfere with neuromuscular transmission.
- Assess disease severity and progression: Helps guide treatment decisions.
- Differentiate from other neuromuscular disorders: Confirms that symptoms are caused by autoimmune activity rather than other conditions.
Tests Typically Included
- Acetylcholine Receptor (AChR) Antibodies
- Detects antibodies targeting acetylcholine receptors on muscle cells.
- Subtypes may include binding, blocking, and modulating antibodies.
- Positive results strongly support a diagnosis of MG.
- Muscle-Specific Kinase (MuSK) Antibodies
- Identifies antibodies against MuSK, another protein essential for neuromuscular signaling.
- Often present in MG patients who test negative for AChR antibodies.
- Lipoprotein-Related Peptide (LRP4) Antibodies (optional, depending on the lab)
- Detects antibodies against LRP4, associated with MG in some patients.
How the Panel Works
- A blood sample is collected and analyzed for the presence of autoantibodies.
- Positive antibodies indicate an autoimmune attack on neuromuscular junctions.
Symptoms Indicating Testing
- Drooping eyelids (ptosis)
- Double vision (diplopia)
- Weakness in arms, legs, neck, or throat
- Difficulty swallowing, chewing, or speaking
- Fatigue that worsens with activity and improves with rest
Test Details
- Sample: Venous blood draw
- Fasting: Not required
- Turnaround Time: Typically 7–10 business days
This panel is a key diagnostic tool for confirming myasthenia gravis and guiding personalized treatment to improve muscle function and quality of life.
